A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 TH1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study

202227 citationsJournal Articlegold Open Access

Authors

https://www.clinicaltrials.gov/, identifier NCT03946358.

Good health and well-being

Published in: Frontiers in Oncology

Volume 12, pp. 957580-957580

Field-Weighted Citation Impact: 5.67